Iovance Biotherapeutics (IOVA) Reports Pivotal Cohort 4 Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel from C-144-01 Clinical Study in Advanced Melanoma

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. IONQ
2. SPY
3. IONS
4. AZN
5. ROIV
6. AAPL
7. ACN
8. USO
9. ORCL
10. HOOD

Go back to Iovance Biotherapeutics (IOVA) Reports Pivotal Cohort 4 Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel from C-144-01 Clinical Study in Advanced Melanoma
(NASDAQ: IOVA) Delayed: 8.74 -0.05 (0.57%)
Previous Close $8.79    52 Week High $ 
Open $8.69    52 Week Low $ 
Day High $8.80    P/E N/A 
Day Low $8.48    EPS $ 
Volume 2,641,690